Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent’s Thought Leader Award Supports Dr. Paul Watkins

Published: Thursday, January 23, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
Dr. Watkins has received the award in recognition of his ongoing work developing integrated methods to predict DILI.

Agilent Technologies Inc. has announced that Dr. Paul B. Watkins, international drug safety expert and director of the Hamner-University of North Carolina Institute for Drug Safety Sciences, has received an Agilent Thought Leader Award in recognition of his ongoing work developing integrated methods to predict drug-induced liver injury (DILI).

This award continues Agilent's support of the research Hamner scientists are conducting on drug induced liver injury (Hamner, 2011).

Dr. Watkins' studies involve mouse genetic models, patients who have experienced or are experiencing DILI, and patient-specific liver culture models derived from stem cells.

"There is an industry-wide need for new predictive tools that will assess the safety of drug compounds much earlier in the drug-development process," said Dr. Watkins, who also chairs the U.S. Drug-Induced Liver Injury Network, funded by the National Institutes of Health. "By integrating a variety of preclinical biological research applications using genetic and genomic data, we hope to better anticipate and prevent patients' possible adverse reactions to bio-pharmaceutical treatment."

Using Agilent's nuclear magnetic resonance technology, SurePrint G3 microarray platform, and other integrated biology technologies, Watkins and his team hope to further elucidate the causes of drug-induced liver injury.

"Patients' susceptibility to adverse reactions appears to involve genetic makeup but is also associated with non-genetic factors, such as age, nutrition and drug interactions," said Dr. Watkins. "We are excited about the progress we are making in understanding this problem, and I am honored to receive the Agilent Thought Leader Award in support of our efforts."

"Drug-induced liver injury is a primary reason why some promising new drug candidates fail during clinical development and why other drugs are pulled off the market," said Dr. John Fjeldsted, Agilent's senior director for LC/MS research and development and executive sponsor of this award.

"We are delighted with the excellent research that Hamner scientists have produced and are very pleased to now recognize Dr. Watkins as an Agilent Thought Leader," he added. "We believe the results of pan-omic studies of drug induced liver damage will make a significant contribution to the understanding of metabolomic, proteomic and genetic associations and lead to more certain toxicity testing in multiple markets."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Agilent to Sponsor Global Forensics Congress in Portugal
Latest LC, GC, MS and mobile-measurement solutions to be featured at September event.
Tuesday, August 27, 2013
Agilent Supports Russell Thomas’ Research at the Hamner Institutes for Health Sciences
Russell supported for his work developing methods to predict drug-induced liver injury.
Thursday, December 08, 2011
Agilent Technologies’ LC/MS Manufacturing Achieves ISO 13485 Certification
6100 Series single quadrupole and 6400 Series triple quadrupole systems now manufactured under ISO 13485 certification.
Monday, September 12, 2011
Agilent Technologies Collaborates with UC Davis on Breakthrough Food-Safety Research
Technology aims to revolutionize food safety by reducing identification time of food-borne bacteria.
Thursday, December 09, 2010
Agilent and Johns Hopkins to Research Toxicity Pathways for Embryonic Brain Development Using Metabolomics
The work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.
Friday, August 20, 2010
BIOCIUS and Agilent Launch High-throughput, RapidFire® Mass Solution for Drug Discovery
Advanced, integrated system for high quality in vitro ADME analysis unveiled at ASMS Conference, May 23-May 27.
Friday, May 21, 2010
Automatic Productivity for Life Science Discovery
Agilent Automation Solutions has announced a 12-page brochure 'Automatic productivity for life science discovery.'
Friday, March 26, 2010
Agilent and the National Center for Food Safety and Technology Collaborate to Develop Food Testing Methods
The collaboration will develop new scientific methods for food testing to solve problems facing global food supply chains.
Wednesday, March 03, 2010
Phytronix and Agilent to Co-Market Phytronix LDTD Ion Source with Agilent Mass Spectrometers
The non-exclusive co-marketing agreement aims to promote the Phytronix Laser Diode Thermal Desorption Ion Source with Agilent mass spectrometers.
Wednesday, June 10, 2009
Regulators OK Agilent buy of Stratagene
Federal Antitrust Regulators Approve Agilent's Purchase of Stratagene
Monday, May 14, 2007
FDA Selects Agilent’s Dual-Mode Platform for MAQC Project
FDA will use Agilent’s dual-mode platform for pharmacogenomics and toxicogenomics studies.
Friday, January 13, 2006
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
Rare Form: Novel Structures Built from DNA Emerge
DNA, the molecular foundation of life, has new tricks up its sleeve. The four bases from which it is composed can be artificially manipulated to construct endlessly varied forms in two and three dimensions.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!